Mitsubishi Tanabe receives approval for Tenelia 20mg tablets in Japan

Tenelia (generic name: Teneligliptin hydrobromide hydrate), a DPP-4 inhibitor created by Mitsubishi Tanabe, is found effective in the treatment of type 2 diabetes mellitus when satisfactory improvement cannot be achieved through a diet and exercise or by combination of both with the use of sulfonylurea- or thiazolidine-class drugs.

The drug increases insulin release and suppresses glucagen release, subsequently inhibit the activity of DPP-4 to lower blood glucose levels.

With once-a-day administration and with its potent and sustained action, Tenelia has made it highly effective in lowering each of the blood glucose postprandial levels, as well as fasting glucose levels.

Daiichi Sankyo and Mitsubishi Tanabe will begin the joint marketing under one brand name – Tenelia 20mg tablets, once the drug is included in the NHI drug price list.